6Y4 Stock Chart & Stats
€0.95
-€0.02(-2.26%)
At close: 4:00 PM EDT
€0.95
-€0.02(-2.26%)
Day’s Range― - ―
52-Week Range€0.77 - €1.86
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€285.46M
Enterprise Value€1.76K
Total Cash (Recent Filing)€1.06B
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Aug 21, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.90
Shares Outstanding281,525,600
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)2.47
Price to Sales (P/S)710.16
P/FCF Ratio-7.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.23Price Target Upside239.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.16
Revenue Forecast (FY)€100.01K
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetZero reported debt and minimal leverage materially reduce near-term financing stress and interest burden. This durable balance-sheet strength gives management flexibility to fund R&D, negotiate partnerships, and extend runway while executing clinical programs over the next several months.
Focused R&D Pipeline (IPF Lead Program)A concentrated, disease-focused pipeline centered on idiopathic pulmonary fibrosis (C21 lead program) creates durable strategic clarity. Specialization can improve development efficiency, enable deeper clinical expertise, and make the company a more attractive partner or acquisition target if clinical data progress.
Positive Gross Profit In TTMMaintaining positive gross profit despite large operating losses implies underlying unit economics or pricing power for revenue-generating activities. That durable signal means operating losses are driven by controllable R&D/SG&A investments rather than broken core economics, easing potential margin recovery if sales scale.
Bears Say
Large Cash Burn And Negative FCFSustained, large negative operating and free cash flow is a structural risk: it creates persistent funding needs and increases the probability of dilutive financing or strategic concessions. Over 2-6 months the company will likely require external capital absent major milestone-driven inflows.
Very Small And Declining Revenue BaseA tiny and shrinking revenue base relative to expense run-rate undermines self-funding prospects. With revenue around single-digit millions versus outsized losses, durable recovery depends on successful clinical or commercial inflection points rather than operational tweaks.
Negative Returns On Equity; Equity ErosionROE near -50% indicates the company's equity base is being consumed by losses, a structural capital-erosion problem. Even with low debt, declining equity reduces the buffer for future setbacks and raises reliance on new capital or strategic deals to sustain development programs.
Vicore Pharma Holding AB News
6Y4 FAQ
What was Vicore Pharma Holding AB’s price range in the past 12 months?
Vicore Pharma Holding AB lowest stock price was €0.77 and its highest was €1.86 in the past 12 months.
What is Vicore Pharma Holding AB’s market cap?
Vicore Pharma Holding AB’s market cap is €285.46M.
When is Vicore Pharma Holding AB’s upcoming earnings report date?
Vicore Pharma Holding AB’s upcoming earnings report date is Aug 21, 2026 which is in 15 days.
How were Vicore Pharma Holding AB’s earnings last quarter?
Vicore Pharma Holding AB released its earnings results on May 06, 2026. The company reported -€0.035 earnings per share for the quarter, beating the consensus estimate of -€0.044 by €0.008.
Is Vicore Pharma Holding AB overvalued?
According to Wall Street analysts Vicore Pharma Holding AB’s price is currently Undervalued.
Does Vicore Pharma Holding AB pay dividends?
Vicore Pharma Holding AB does not currently pay dividends.
What is Vicore Pharma Holding AB’s EPS estimate?
Vicore Pharma Holding AB’s EPS estimate is -0.04.
How many shares outstanding does Vicore Pharma Holding AB have?
Vicore Pharma Holding AB has 281,525,600 shares outstanding.
What happened to Vicore Pharma Holding AB’s price movement after its last earnings report?
Vicore Pharma Holding AB reported an EPS of -€0.035 in its last earnings report, beating expectations of -€0.044. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Vicore Pharma Holding AB?
Currently, no hedge funds are holding shares in DE:6Y4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vicore Pharma Holding AB
Vicore Pharma Holding AB (publ), a Gothenburg, Sweden-based company, specializes in the discovery and advancement of therapies for rare lung conditions. Its core pipeline features VP01, an orally administered small molecule currently in Phase II clinical trials for indications such as interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19. The company is also progressing VP02, a novel formulation and delivery approach for an established immunomodulatory compound, which is in preclinical development for treating IPF. Vicore maintains strategic alliances, including a development cooperation with Emeriti Bio AB, a licensing arrangement with Nanologica AB (publ), and a collaboration with Alex Therapeutics AB focused on creating and clinically validating a digital therapeutic (DTx) built on the Alex DTx platform. Established in 2000, the company was formerly known as Mintage Scientific AB.
6Y4 Stock 12 Month Forecast
Average Price Target
€3.23
▲(239.56% Upside)
Technical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
SynAct Pharma AB
―
Xspray Pharma AB
―
Cantargia AB
―